Tetherex: Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform
Tetherex Pharmaceuticals, Inc. today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
Read full article »
Tetherex Pharmaceuticals focuses on the development of novel selectin inhibitor products to treat thrombosis, inflammatory diseases and cancer.
Read more